Regeneron’s Garetosmab BLA Receives FDA Priority Review, Decision Due in August
Regeneron’s Biologics License Application for garetosmab in fibrodysplasia ossificans progressiva has been accepted by the FDA for Priority Review, with a decision expected by August. Phase 3 OPTIMA trial data showed a 90–94% reduction in new bone lesions over 56 weeks and a post-hoc analysis revealed over 99% reduction in lesion volume.
1. FDA Priority Review Acceptance
On February 19, the FDA accepted Regeneron’s Biologics License Application for garetosmab under Priority Review, targeting fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder. The agency is scheduled to reach a decision by August, expediting potential market entry for the first approved FOP therapy.
2. Phase 3 OPTIMA Trial Results
The Phase 3 OPTIMA trial in adult FOP patients demonstrated a 90–94% reduction in new bone lesion count over 56 weeks compared with placebo. A post-hoc analysis further revealed a greater than 99% reduction in the total volume of new abnormal bone formation, underscoring garetosmab’s pronounced efficacy.
3. Next Steps and Market Implications
Garetosmab targets Activin A, identified by Regeneron scientists as the key driver of ectopic bone growth in FOP. Regeneron plans to initiate the OPTIMA 2 trial in children and adolescents later this year, positioning the company to capture the entire FOP patient population upon approval.